Abstract
Abstract Objective The article presents the current state of knowledge on diagnosis, rehabilitation and pharmacological treatment of neuropsychological impairment in schizophrenia. Review Cognitive functioning is moderately to severely impaired in patients with schizophrenia. There is a growing number of diagnostic methods translated into Polish that enable mental health professionals to evaluate and describe cognitive deficits. Some available tools include: MATRICS Consensus Cognitive Battery (MCCB), Brief Cognitive Assessment Tool for Schizophrenia (B-CATS), Montreal Cognitive Assessment (MoCA) and Brief Assessment of Cognition in Schizophrenia (BACS). There is also an increasing number of rehabilitation programmes that support therapy of cognitive impairment such as Social Cognition and Neurocognition Training, RehaCom, COGPACK and Neuroforma. Conclusion The use of current knowledge, accurate neuropsychological diagnosis, the use of an appropriate cognitive rehabilitation programme and pharmacotherapy may have a significant impact on quality of life and functioning of patients with schizophrenia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
